CEA is overexpressed in over 90% of pancreatic cancers, and represents a potential target for immunotherapy [20], although no completed clinical trial has been reported in pancreatic malignancy so far [21]. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.